Analysts Pound the Table on This ‘Strong Buy’ Coronavirus Stock

A journey of a thousand miles begins with a single step, and a big one in this case. Last week, COVID vaccine researcher…

Vaxart (VXRT) reported preclininal study results suggesting ingestion of its oral coronavirus vaccine VXA-CoV2-1 helped to reduce viral loads in lab hamsters.

Indeed, according to Vaxart, the new vaccine appeared to provoke “a broader immune response that has the potential to offer superior protection against SARS-CoV-2,” than comparable injectable vaccines. Moreover, because oral vaccinations are obviously less stressful for patients (show me a patient who prefers needles to pills, if you disagree), investors logically took the study results — preliminary as they are — as a good sign for Vaxart stock.

Among the fans are analysts Kumaraguru Raja at Brookline Capital Markets and Mayank Mamtani at B. Riley Securities, who sing Vaxart’s praises in the wake of the company’s VXA-CoV2-1 news.

What made them so optimistic?

Brookline’s Raja notes that Vaxart’s news resulted from a “Hamster Challenge” study preparatory to Phase 1 clinical trials. Vaxart says that enrollment of patients to begin those Phase 1 trials has already completed, however, and Raja predicts that investors will be treated to “positive initial data before year end” — a potential catalyst that could drive up the stock price long before Vaxart has a chance to report any more earnings (or losses) news. That right there sounds propitious for a start.

Moving all the way through Phase 3 trials (assuming the vaccine gets that far) could still take the entirety of next year, with distribution beginning no sooner than early 2022. On the one hand, that means Vaxart is going to be getting a pretty late start relative to all the other vaccines coming to market. However, on the other hand, Raja also points out that…

Continue reading at YAHOO! FINANCE



You May Also Like

About the Author: admin

Leave a Reply

Your email address will not be published.